$15.25 (0%)

Volume: 0

Closed: Feb 17, 2023

Hollow Logo Score: 0.000
Aerie Pharmaceuticals Stock
Open Broker Account NASDAQ:AERI Delisted
$15.25 (0%)

Volume: 0

Closed: Feb 17, 2023

Score Hollow Logo 0.000

Aerie Pharmaceuticals Stock Company Profile

4301 Emperor Boulevard, Suite 400

Durham NC 27703

919 237 5300


Aerie Pharmaceuticals


Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE